Clinical trial · Interventional
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Transplantation, Hematopoietic Stem Cell | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Caspofugin based combination therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Caspofugin based combination therapy
- description
- Caspofugin based combination therapy: Patients will recieve caspofungin with voriconazole or amphotericin B
- interventionNames
- Drug: Caspofugin based combination therapy
Primary outcomes (1)
- measure
- Favorable response rate
- timeFrame
- 12 weeks
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- 12 weeks, 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * adult patient undergoing allogeneic hematopoietic stem cell transplantation * age 18-55 years * with inform consent * no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage * HLA mismatched related (3\~5/6) or unrelated donors (at least 8/10) * proven or probable IFI Exclusion Criteria: * age less than 18 years or over 56 years * HLA mismatched related donor * liver function/renal function damage (over 2 X upper normal range) * with mental disease
References
Publications (0)
Data not yet available